Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Xvivo: Results From Clinical Trial NIHP2019 For Heart Preservation

April 11 (Reuters) - Xvivo Perfusion AB  XVIVO.ST :
    * RESULTS FROM XVIVO’S CLINICAL TRIAL NIHP2019 FOR HEART
PRESERVATION PRESENTED AT ISHLT IN PRAGUE
    * PRIMARY ENDPOINT, REPRESENTING SEVERE COMPLICATIONS AFTER
HEART
TRANSPLANTATION, WAS REGISTERED IN 18.8% OF SUBJECTS WHO
RECEIVED A DONOR HEART PRESERVED WITH XVIVO HEART ASSIST
TRANSPORT
    * 30.1% OF SUBJECTS IN CONTROL GROUP WHO RECEIVED A DONOR
HEART
TRANSPORTED ON ICE

Source text for Eikon:  ID:nMFN55cnTM 
Further company coverage:  XVIVO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Xvivo Perfusion AB

See all news